Exabis Library
Welcome to the e-CCO Library!
P517: Features of cytomegalovirus infection in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P517: One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P518 Ulcerative colitis drug development success rates are higher than the industry average
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P518: Cardiovascular Risk Factors in Adolescents with inflammatory bowel disease: A Cross-sectional Population-Based Study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P518: Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic review
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P518: Remission induction in corticosteroid naïve children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P519: Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P519: Anti-tumour necrosis-alpha therapy during pregnancy in patients with inflammatory bowel disease: safety in women and children
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P519: Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P519: Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P519: Post-surgical recurrence predictors in the years 2000. Results of a retrospective single-centre long-term follow-up series and impact of imaging findings on outcomes
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM